Browse Studies — Arctuva

Phase 1

A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors

This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and prelimina…

Safety IssuesTolerabilityPharmacokinetics

Estimated

~$10 – $8,750

Nanjing Immunophage Biotech Co., LtdNCT05142592

Observing the Acute Effects Following a Single Oral Dose of Kratom and Effects Following Kratom Cessation Among Adults Who Use Regularly.

The goal of this observational clinical study is to is to learn more about how commercial kratom products affect healthy adults who consume them regularly. The…

Kratom PharmacokineticsKratom PharmacodynamicsKratom

Estimated

~$10 – $750

Johns Hopkins UniversityNCT06089980

Preliminary Characterization of Commercial Kratom Extract Products

To understand the acute subjective, physiological, and cognitive effects of commercial kratom extract products among US adults who consume these products regul…

Kratom PharmacodynamicsKratom Pharmacokinetics

Estimated

~$10 – $750

Johns Hopkins UniversityNCT06640569

Phase 1

Pharmacokinetics of Oral Calcium Carbonate in Parturients

This study investigates the time course of change in calcium in the blood after a pregnant subject takes an oral dose of calcium carbonate (commonly marketed a…

PregnancyPharmacokineticsPostpartum Hemorrhage

Estimated

~$10 – $6,250

Stanford UniversityNCT06650930